NEW YORK (GenomeWeb News) – RNAi research services company Definiens said today that Cenix BioScience has expanded a license agreement to continue to use Definiens’ data extraction technology in its microscopy assays for high throughput RNAi studies in human and rodent cells.
Under the agreement, Cenix will integrate the Definiens Cellenger system into its existing high-throughput and high-content RNAi-based research infrastructure, the company said.
The Cellenger system is an application for high content analysis that enables fully automated extraction of data from images in cell-based assays. Using the system allows Cenix to accurately study “subjects of interest even in complex images with high accuracy.”
Financial terms of the agreement were not released.